Narcan challenge. See naloxone challenge test

missed doses, 85

Narcotic Addict Treatment Act of 1974, 21, 25

mobile treatment units, 90

narcotics farms, 15

models of care, 202

Narcotics Register, New York City, 16

money management, 60

monotherapy tablets, 69

Narcotic Treatment Programs: Best Practice

Guideline, 237

morphine, 12ñ17

National Institutes of Health consensus panel

duration of action, 217

recommendations, 4, 20

and neonatal abstinence syndrome, 219

necrotizing fasciitis, 163ñ164

and pain management, 174ñ175

Neonatal Abstinence Score, 219

motivational enhancement, 130

neonatal abstinence syndrome, 216, 218ñ219

motivational interviewing, 53

and buprenorphine, 220ñ221

Motivational Interviewing: Preparing People

and methadone, 219

for Change, 130

nicotine, effects of, 185

motivation for seeking treatment, 54, 96, 107,

and pregnancy, 212

191

node-link mapping, 128

multidisciplinary treatment team, 100

nonmalfeasance, principle of medical ethics,

multiple substance use, 48, 106, 111

298

and co-occurring disorders, 181

nutrition, and pregnancy, 223ñ224

and dosage adjustments, 187

Nyswander, Dr. Marie E., 17

and increased drug testing, 188

management of, 186

O

and morbidity and mortality, 181

and pregnancy, 217

OBOT. See office-based opioid treatment

prevalence of, 180, 181

observed dosing, 65ñ66

and psychosocial treatment services, 187ñ188

office-based opioid treatment, 6, 63, 85, 90

mu opiate receptors, 28, 29

with methadone, 115

and buprenorphine, 30

opioid addiction

and methadone, 29

diagnosing in pregnant patients, 212

and naltrexone, 30

history of, 11ñ12

mutual-help programs

as a medical disorder, 3ñ5

and conflict with MAT, 135

opioid agonist, 64

and patientñtreatment matching, 88

definition, 28

for people with co-occurring disorders, 203

side effects of, 34

Web sites for, 136, 203

opioid analgesic abuse, 14

opioid antagonist, 5, 19

N

and diagnosing addiction in pregnant

women, 212

naloxone-buprenorphine combination. See

buprenorphine, SuboxoneÆ

side effects of, 34

opioid overdose, 50

naloxone challenge test, 50, 70

opioid pharmacotherapy

naltrexone, 5

contraindications to, 64ñ65

development of, 19

stages of, 65

dosage forms, 32

opioid treatment programs

dose levels, 72

administrative considerations, 225

efficacy of, 33

attendance requirements, 124

induction stage of pharmacotherapy, 70

and co-occurring medical and mental

and overdose, 42

disorders, 91

pharmacology and pharmacotherapy of, 30ñ31

definition, 2

safety of, 42

and duty to warn, 202

side effects of, 35

324

Index